Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says

Published 12/04/2024, 15:40
Updated 12/04/2024, 17:11
©  Reuters Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
LLY
-
SNY
-
AZN
-
NVO
-

Benzinga - by Vandana Singh, Benzinga Editor.

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has determined that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists (GLP-1) and suicidal or self-injurious thoughts and behaviors.

The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a review of GLP-1 RAs.

The FDA released an update stating that its preliminary review did not show definitive evidence that the drugs cause suicidal thoughts or actions.

GLP-1 receptor agonists, including dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, are commonly prescribed for treating type 2 diabetes and, under specific conditions, for managing weight in obese or overweight adults.

The review was initiated in July 2023, prompted by reports of suicidal ideation among users of liraglutide and semaglutide medications.

In November 2023, the committee requested additional data from the marketing authorization holders for these medications, including Novo Nordisk A/S’s (NYSE:NVO) Ozempic, Rybelsus, Wegovy, Saxenda, Victoza, and Xultophy; AstraZeneca Plc’s (NASDAQ:AZN) Byetta and Bydureon; Sanofi SA’s (NASDAQ:SNY) Lyxumia, and Suliqua; and Eli Lilly And Co’s (NYSE:LLY) Trulicity.

Furthermore, the committee scrutinized the outcomes of a recent study based on a vast electronic health records database.

This study, which investigated the incidence of suicidal ideation in overweight patients with type 2 diabetes receiving semaglutide or other non-GLP-1 receptor agonist medications, found no direct link between semaglutide usage and suicidal thoughts.

The EMA conducted a study using electronic health records to investigate the risk of suicide and self-injury in people with type 2 diabetes using GLP-1 receptor agonists.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

They found no evidence establishing a direct link between these medications and the mentioned risks.

Following a review of various data sources, including non-clinical studies, clinical trials, and post-marketing surveillance data, the PRAC concluded that no revision to the product information is necessary.

The PRAC determined that no changes to the product information are needed. The medication companies will continue monitoring these events and updating their safety reports accordingly.

Additionally, the PRAC approved a communication plan to inform healthcare professionals about differences between current and proposed formulations of Rybelsus, an oral semaglutide medication for poorly controlled type 2 diabetes.

Price Action: NVO shares are up 0.41% at $125.91 on the last check Friday.

Image By Natalia Varlei On Shutterstock

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.